Akari Therapeutics Plc
(NASDAQ : AKTX)

( )
AKTX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co.
-0.27%63.771.4%$1739.02m
JNJJohnson & Johnson
0.07%141.440.7%$876.14m
PFEPfizer Inc.
-0.55%38.330.9%$729.42m
MRKMerck & Co., Inc.
0.32%89.240.7%$685.29m
ABBVAbbVie, Inc.
-1.07%87.782.3%$607.65m
LLYEli Lilly & Co.
-0.14%121.531.1%$364.17m
NVSNovartis AG
0.25%93.290.2%$151.08m
AZNAstraZeneca Plc
0.92%48.361.2%$138.40m
GSKGlaxoSmithKline Plc
0.13%45.990.2%$137.93m
SNYSanofi
0.57%49.790.2%$114.51m
RETAReata Pharmaceuticals, Inc.
2.84%206.753.5%$108.66m
KRTXKaruna Therapeutics, Inc.
-11.24%65.250.0%$105.65m
NVONovo Nordisk A/S
1.33%57.250.1%$92.18m
ALLKAllakos, Inc.
-2.21%123.190.0%$74.02m
FTSVForty Seven, Inc.
-7.72%35.750.0%$50.91m

Company Profile

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.